SGLT2 inhibitors showed robust respiratory protection that appeared largely independent of diabetes status, GLP-1 receptor agonists may provide benefit in obesity, and DPP-4 inhibitors offered limited advantage with a potential asthma risk. Here, SLC5A2 is linked to obesity disorder.